View Post

GT Biopharma Announces TriKE™ For The Treatment Of Breast And GI Cancers

In Clinical Trials by Barbara Jacoby

Source: GT Biopharma, Inc. From: GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) an immuno-oncology company focused on innovative therapies based on the Company’s proprietary NK cell engager (TriKE™) technology platform is pleased to announce the filing of U.S. and international patent applications, and the initiation of clinical development of TriKE™ therapy for the treatment of HER2+, HER3+ and HER2+/HER3+ heterodimer …